GlassScriptPhysician profile
Beth S Pearce
NPI 1568432722
$27,388.14
in general payments reported to CMS, 2019-2025
32 companies · $585 in 2025
The $585 reported for 2025 was more than what 75% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $16K · 2021: $6,557 · 2022: $1,436 · 2023: $220 · 2024: $464 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $23,286.80 | 2019-2022 | |
| Biotissue Holdings INC. | $915.09 | 2019-2025 | |
| Wright Medical Technology, INC. | $473.73 | 2019 | |
| Arthrex, INC. | $442.00 | 2019 | |
| Amniox Medical, INC. | $380.60 | 2019 | |
| Organogenesis INC. | $322.58 | 2021-2025 | Puraply, Novachor |
| Medtronic, INC. | $217.69 | 2024-2025 | Abre, Inceptiv, Closurefast |
| Nevro Corp. | $214.14 | 2022-2024 | Senza |
| Smith+Nephew, INC. | $165.10 | 2020-2025 | Grafix Pl, Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $158.95 | 2021-2025 | Nuzyra |
| Horizon Therapeutics Plc | $125.76 | 2019-2021 | |
| Grt US Holding, INC. | $98.55 | 2021-2022 | |
| Amgen INC. | $69.01 | 2025 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $55.65 | 2021-2022 | |
| Integra Lifesciences Corporation | $52.26 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $47.69 | 2022-2025 | Physio-Stim |
| Convatec INC. | $41.31 | 2023-2024 | |
| Acera Surgical, INC. | $35.83 | 2022 | |
| Curonix LLC | $33.07 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $31.66 | 2025 | |
| Bioventus LLC | $30.57 | 2022 | |
| Next Science LLC | $27.94 | 2023-2024 | Surgx, Blastx, Xperience |
| Averitas Pharma INC. | $25.62 | 2025 | Qutenza |
| Sanara Medtech INC. | $23.26 | 2022 | |
| Kerecis Limited | $17.44 | 2022 | |
| Alfasigma USA, INC. | $16.04 | 2021 | |
| Innovation Technologies INC | $15.82 | 2025 | Irrisept |
| Heron Therapeutics, INC. | $14.81 | 2021 | |
| Triad Life Sciences INC. | $13.60 | 2022 | |
| Zimvie INC. | $13.08 | 2023 | |
| Djo, LLC | $12.13 | 2021 | |
| Reprise Biomedical, INC. | $10.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.